

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



AUSTAR

Austar Lifesciences Limited

奥星生命科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6118)

PROFIT WARNING

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules).

The board (“**Board**”) of directors (“**Directors**”, each a “**Director**”) of Austar Lifesciences Limited (“**Company**”) and together with its subsidiaries, the “**Group**”) wishes to inform the shareholders of the Company and potential investors that, based on information currently available, the Group is expected to incur a loss attributable to the shareholders of the Company for the six months ending 30 June 2016, as compared to a profit attributable to the shareholders of the Company of approximately RMB10,144,000 for the corresponding period in 2015. Such loss is mainly attributable to (i) prolonged execution time for certain projects undertaken by the Group during the period resulting in a decrease in the overall revenue of the Group and an increase in budgeted costs as compared with the corresponding period in 2015; and (ii) decrease in the overall gross profit margin for the projects undertaken by the Group as compared with the corresponding period in 2015 as certain projects with a relatively lower gross profit margin being undertaken by the Group during the period for the purpose of retaining customers.

As the period covered by the six months ending 30 June 2016 has not yet ended, the information contained in this announcement is only based on the preliminary assessment by the management of the Company by information currently available to the Group including the unaudited consolidated management accounts of the Group for four months ended 30 April 2016 and is not based on any figure or information which has been audited or reviewed by the Company’s auditors. Notwithstanding the anticipated loss, the Board believes that overall financial position of the Group remains healthy. Details of the Group’s financial information and performance will be disclosed when the Group’s interim results for the six months ending 30 June 2016 are announced.

Shareholders of the Company and potential investors should exercise caution when dealing in the shares of the Company.

On behalf of the Board
Austar Lifesciences Limited
Ho Kwok Keung, Mars
Chairman and Chief Executive Officer

Hong Kong, 27 May 2016

As at the date of this announcement, the Board comprises four executive Directors, namely Mr. Ho Kwok Keung, Mars, Mr. Ho Kin Hung, Mr. Chen Yuewu and Madam Zhou Ning; one non-executive Director, namely Madam Ji Lingling; and three independent non-executive Directors, namely Mr. Cheung Lap Kei, Madam Chiu Hoi Shan and Mr. Raco Ivan Jordanov (alias Racho Jordanov)